表紙:英国のファーマコビジランスの市場動向・市場シェア・市場規模の予測 (2021-2028年):サービスプロバイダー (契約アウトソーシング・社内)・製品ライフサイクル・タイプ・プロセスフロー・治療領域・エンドユーザー別
市場調査レポート
商品コード
1030927

英国のファーマコビジランスの市場動向・市場シェア・市場規模の予測 (2021-2028年):サービスプロバイダー (契約アウトソーシング・社内)・製品ライフサイクル・タイプ・プロセスフロー・治療領域・エンドユーザー別

U.K. Pharmacovigilance Market Size, Share & Trends Analysis Report By Service Provider (Contract Outsourcing, In-house), By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-use, And Segment Forecasts, 2021 - 2028

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 186 Pages | 納期: 2-10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
英国のファーマコビジランスの市場動向・市場シェア・市場規模の予測 (2021-2028年):サービスプロバイダー (契約アウトソーシング・社内)・製品ライフサイクル・タイプ・プロセスフロー・治療領域・エンドユーザー別
出版日: 2021年09月29日
発行: Grand View Research, Inc.
ページ情報: 英文 186 Pages
納期: 2-10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

英国のファーマコビジランスの市場規模は予測期間中11.9%のCAGRで推移し、2028年には5億1037万米ドルの規模に成長すると予測されています。

製薬企業やバイオテクノロジー企業の大半が臨床試験のアウトソーシングを進めていることや、臨床試験の実施に関する遵守義務、市販後調査などの要因が予測期間中の大幅な市場成長を促進する見通しです。さらに、クラウドベースのPVプラットフォームなど、技術的に高度でユーザーフレンドリーなソフトウェアシステムの導入も今後数年の市場を牽引すると予測されています。

当レポートでは、英国のファーマコビジランスの市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、技術タイムライン、市場規模の推移・予測、サービスプロバイダー・タイプ・製品ライフサイクル・プロセスフロー・治療領域・エンドユーザーなど各種区分別の内訳、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 ファーマコビジランス市場の可変因子・動向・展望

  • 市場の見通し
  • 普及・成長の見通しマッピング
  • 市場力学
  • ポーターの分析
  • SWOT分析
  • バリューチェーン分析
  • ライフサイクルマッピング
  • 規制の枠組み
  • 組織構造
  • 価格設定モデル
  • 技術タイムライン

第4章 COVID-19:影響分析

第5章 ファーマコビジランスの市場推計・動向分析:サービスプロバイダー別

  • 市場シェア分析
  • ダッシュボード
    • 社内
    • 契約アウトソーシング

第6章 ファーマコビジランスの市場推計・動向分析:タイプ別

  • 市場シェア分析
  • ダッシュボード
    • 自発報告
    • 強化ADR報告
    • ターゲット自発報告
    • コホートイベントモニタリング(CEM)
    • EHRマイニング

第7章 ファーマコビジランスの市場推計・動向分析:製品ライフサイクル別

  • 市場シェア分析
  • ダッシュボード
    • 前臨床
    • フェーズI
    • フェーズII
    • フェーズIII
    • フェーズIV

第8章 ファーマコビジランス市場の市場推計・動向分析:プロセスフロー別

  • 市場シェア分析
  • ダッシュボード
    • ケースデータ管理
    • 信号検出
    • リスク管理システム

第9章 ファーマコビジランスの市場推計・動向分析:治療領域別

  • 市場シェア分析
  • ダッシュボード
    • 腫瘍
    • 神経
    • 心臓病
    • 呼吸器
    • その他

第10章 ファーマコビジランスの市場推計・動向分析:エンドユーザー別

  • 市場シェア分析
  • ダッシュボード
    • 医薬品
    • バイオテクノロジー企業
    • 医療機器メーカー
    • その他

第11章 競合の見通し

  • 市場参加の分類
  • 公開企業
  • 非公開企業

第12章 企業プロファイル

  • Accenture
  • IQVIA
  • Cognizant
  • IBM Corporation
  • ArisGlobal
  • ICON Plc.
  • Capgemini
  • TAKE Solutions
  • PAREXEL International Corporation
  • BioClinica, Inc.

第13章 勝利戦略

図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation
  • Table 3 Types of ADRs
  • Table 4 Adverse Drug Events (ADEs) in hospitals
  • Table 5 Total literature searches (2013 - 2019)
  • Table 6 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
  • Table 7 Case management costing by year
  • Table 8 Price by case processing volume
  • Table 9 Outsourcing trend observed in pharmaceutical companies
  • Table 10 List of Major Deals & Acquisitions
  • Table 11 Detailed list of companies in clinical trials in pharmacovigilance

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
  • Fig. 10 U.K. Pharmacovigilance Market Estimates and Revenue Forecast, 2016 - 2028 (USD Million)
  • Fig. 11 U.K. Pharmacovigilance market snapshot, 2020 (USD Million)
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Pharmacovigilance market dynamics
  • Fig. 14 Pharmacovigilance market driver impact
  • Fig. 15 Pharmacovigilance market restraint impact
  • Fig. 16 Porter's five force model
  • Fig. 17 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 18 Trending topics on social media (2017)
  • Fig. 19 ADR detection and from social media data
  • Fig. 20 Common literature automation tool flow
  • Fig. 21 Automation processes in PV
  • Fig. 22 Deterrents to Leveraging the Cloud (Oracle Survey)
  • Fig. 23 The three-step process to compute signal statistics from search log using big data
  • Fig. 24 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
  • Fig. 25 Pharmacovigilance & Patient Safety Services - Product Life Cycle
  • Fig. 26 PV department
  • Fig. 27 PV organization structure
  • Fig. 28 Estimated budget allocation of drug safety activities at global and country-level
  • Fig. 29 Comparison between estimated global and country-level drug safety budget allocation
  • Fig. 30 Average % of drug safety budget contributed by function at a global level
  • Fig. 31 Clinical trial cost by phase (%)
  • Fig. 32 The average monthly cost of illness due to ADRs
  • Fig. 33 Covid-19 disease prevalence analysis
  • Fig. 34 Pharmacovigilance market: Product life cycle movement analysis
  • Fig. 35 Pharmacovigilance market product life cycle dashboard
  • Fig. 36 Preclinical market, 2016 - 2028 (USD Million)
  • Fig. 37 Phase I market, 2016 - 2028 (USD Million)
  • Fig. 38 Phase II market, 2016 - 2028 (USD Million)
  • Fig. 39 Phase III market, 2016 - 2028 (USD Million)
  • Fig. 40 Phase IV market, 2016 - 2028 (USD Million)
  • Fig. 41 U.K. Pharmacovigilance market: Service provider movement analysis
  • Fig. 42 Pharmacovigilance Service provider dashboard
  • Fig. 43 In-house market, 2016 - 2028 (USD Million)
  • Fig. 44 Contract outsourcing market, 2016 - 2028 (USD Million)
  • Fig. 45 U.K. Pharmacovigilance market: Type movement analysis
  • Fig. 46 Pharmacovigilance type dashboard
  • Fig. 47 Spontaneous reporting market, 2016 - 2028 (USD Million)
  • Fig. 48 Intensified ADR reporting market, 2016 - 2028 (USD Million)
  • Fig. 49 Targeted spontaneous reporting market, 2016 - 2028 (USD Million)
  • Fig. 50 CEM market, 2016 - 2028 (USD Million)
  • Fig. 51 EHR mining market, 2016 - 2028 (USD Million)
  • Fig. 52 U.K. Pharmacovigilance market: Process flow movement analysis
  • Fig. 53 U.K. Pharmacovigilance market process flow dashboard
  • Fig. 54 Case data management market, 2016 - 2028 (USD Million)
  • Fig. 55 Case logging market, 2016 - 2028 (USD Million)
  • Fig. 56 Case data analysis market, 2016 - 2028 (USD Million)
  • Fig. 57 Medical reviewing and reporting market, 2016 - 2028 (USD Million)
  • Fig. 58 Signal detection market, 2016- 2028 (USD Million)
  • Fig. 59 Adverse event logging market, 2016 - 2028 (USD Million)
  • Fig. 60 Adverse event analysis market, 2016 - 2028 (USD Million)
  • Fig. 61 adverse event review & reporting market, 2016 - 2028 (USD Million)
  • Fig. 62 Risk management system market, 2016 - 2028 (USD Million)
  • Fig. 63 Risk Evaluation System market, 2016 - 2028 (USD Million)
  • Fig. 64 Risk mitigation system market, 2016 - 2028 (USD Million)
  • Fig. 65 U.K. Pharmacovigilance market: Therapeutic area movement analysis
  • Fig. 66 Pharmacovigilance market therapeutic area dashboard
  • Fig. 67 Oncology market, 2016 - 2028 (USD Million)
  • Fig. 68 neurology market, 2016 - 2028 (USD Million)
  • Fig. 69 cardiology market, 2016 - 2028 (USD Million)
  • Fig. 70 respiratory systems market, 2016 - 2028 (USD Million)
  • Fig. 71 others market, 2016 - 2028 (USD Million)
  • Fig. 72 U.K. Pharmacovigilance market: End-use movement analysis
  • Fig. 73 Pharmacovigilance market end-use dashboard
  • Fig. 74 Pharmaceuticals market, 2016 - 2028 (USD Million)
  • Fig. 75 Biotechnology companies' market, 2016 - 2028 (USD Million)
  • Fig. 76 Medical device manufacturers market, 2016 - 2028 (USD Million)
  • Fig. 77 Others market, 2016 - 2028 (USD Million)
  • Fig. 78 Market participant categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Organization Structure - Accenture
  • Fig. 81 SWOT - Accenture
  • Fig. 82 Organization Structure - IQVIA
  • Fig. 83 SWOT - IQVIA
  • Fig. 84 Organization Structure - Cognizant
  • Fig. 85 SWOT - Cognizant
  • Fig. 86 Organization Structure - IBM
  • Fig. 87 SWOT - IBM
  • Fig. 88 Organization Structure - ArisGlobal
  • Fig. 89 SWOT - ArisGlobal
  • Fig. 90 Organization Structure - ICON Plc
  • Fig. 91 SWOT - ICON Plc
  • Fig. 92 Organization Structure - Capgemini
  • Fig. 93 SWOT - Capgemini
  • Fig. 94 Organization Structure - Take Solutions
  • Fig. 95 SWOT - Take Solutions
  • Fig. 96 Organization Structure - Paraxel Corporation
  • Fig. 97 SWOT - PARAXEL
  • Fig. 98 Organization Structure - BioClinica, Inc.
  • Fig. 99 SWOT - BioClinica, Inc.
  • Fig. 100 Commonly outsourced PV activities
  • Fig. 101 Vendor selection criteria
目次
Product Code: GVR-4-68039-547-3

U.K. Pharmacovigilance Market Growth & Trends:

The U.K. pharmacovigilance market size is expected to reach USD 510.37 million by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 11.9% from 2021 to 2028. The increasing outsourcing and externalization of clinical trials by the majority of the pharmaceutical and biotechnological companies, regulatory mandates on clinical trial conduct, and post-marketing vigilance are likely to drive the market at an unprecedented rate throughout the forecast period.

Moreover, the introduction of technologically advanced and user-friendly software systems, such as cloud-based PV platforms, is anticipated to drive the market in the coming years. In June 2017, Genpact launched Pharmacovigilance Artificial Intelligence ("PVAI") solution to alter drug safety data management and reporting. While in December 2020, the Medicines and Healthcare products Regulatory Authority (MHRA) signed a deal with Genpact for obtaining the PVAI tool for USD 2.07 million. In that way, the U.K. became one of the world's first drug regulators to usage an AI tool to record and process adverse drug reactions.

Throughout the past decade, the augmented usage of numerous expedited review approaches and other developments have led to a decline in the time taken to bring new drugs to the market. While this hastening has led to more quick access for patients, it also upsurges the risk of adverse drug reactions being spotted for the first time when the product is already in the market, leading to the higher demand for post-approval safety surveillance studies and related actions. This is eventually supporting the overall market growth.

Although COVID-19 is forcing many medical device and drug developers to revise their approach to handle the crisis, integrating best practices within clinical trial procedures and adoption of virtual trials can support the constant progress of therapeutics in the pandemic environment. For instance, PPD deployed remote site-monitoring tools to replace on-site visits for COVID-19safety, enabling trial continuation. An increase in R&D and the adoption of new technologies in clinical research are likely to further drive the market. For instance, in April 2020, IBM launched AI-based technologies and COVID-19 high-performance computing consortium to assist research and health communities and accelerate the discovery of medical insights and treatments for COVID-19.

The rising number of contract research organizations and increased demand for outsourcing services are expected to fuel the market competition among market players in the near future. Key participants are involved in continuous product development, partnerships, mergers, and acquisitions to augment market penetration. For instance, in march 2021, ProPharma Group acquired Diamond Pharma Services. This acquisition will help in solidifying ProPharma Group's position as the leading global provider of regulatory, compliance, pharmacovigilance, and medical information services.

U.K. Pharmacovigilance Market Report Highlights:

  • By product life cycle, phase IV dominated the market in 2020 phase IV clinical studies are complex in design and large in scale. Besides, this is an imperative phase of clinical trials as unanticipated adverse drug reactions can be spotted in this phase
  • In terms of service provider, contract outsourcing held a dominant share in 2020 owing to the rapidly emerging CROs providing end-to-end clinical trial solutions and outsourcing trends in the pharmaceutical, biotechnology, and medical devices industries. In January 2018, Concept Life Sciences and Alderley Analytical signed a partnership contract to deliver high-value bio analytical and DMPK study services
  • Based on type, spontaneous reporting held the largest share of over 30.0% in 2020 owing to its wide usage in the detection of new, serious, and rare ADRs and its popularity as an efficient and inexpensive method. Spontaneous reporting during the post marketing phase produces most drug safety data, yet more than clinical trials during drug development, thereby boosting demand
  • On the basis of process flow, the case data management segment is expected to witness the fastest growth over the forecast period. The adverse event information can be generated from various modes, such as post-marketing programs, clinical trials, spontaneous reports, and literature. Some of the data management software include PV-Works Human, ClinSource, and Oracle
  • The oncology therapeutic area segment held the largest share of over 25.0% in 2020. Monitoring the safety of cancer drugs is very important due to the associated side effects, which is propelling the demand for pharmacovigilance services
  • The biotechnology companies end-use segment is anticipated to exhibit the highest CAGR of 12.6% over the forecast period. The number of U.K. biotechnology corporations has boomed, growing by 65% since 2016

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Service Provider
    • 1.1.2 Type
    • 1.1.3 Product Life Cycle
    • 1.1.4 Process Flow
    • 1.1.5 Therapeutic area
    • 1.1.6 End use
    • 1.1.7 Country Scope
    • 1.1.8 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details of Primary Research
      • 1.3.5.1 Data for primary interviews
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Market Definitions
  • 1.10 Report Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 U.K. Pharmacovigilance Market Outlook, 2016 - 2028 (USD Million)
  • 2.3 Segment Outlook
  • 2.4 Competitive Outlook

Chapter 3 Pharmacovigilance Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market analysis
    • 3.1.2 Ancillary market Analysis
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Pharmacovigilance Market Dynamics
    • 3.3.1 Market driver analysis
    • 3.3.2 Market restraint analysis
    • 3.3.3 Industry Challenges
  • 3.4 U.K. Pharmacovigilance Market Analysis Tools: Porters
  • 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
  • 3.6 Value Chain Analysis
    • 3.6.1 Pre-clinical
    • 3.6.2 Clinical
    • 3.6.3 PMA
  • 3.7 Mapping of Life Cycle Against Service Offering and Their Demand
  • 3.8 Regulatory Framework
  • 3.9 Pharmacovigilance: Organization Structure Introduction
  • 3.10 Pricing Models
    • 3.10.1 Drug safety Budget Allocation by Activities
    • 3.10.2 By Development phase
    • 3.10.3 By Therapeutic area
    • 3.10.4 Pricing Level
      • 3.10.4.1 Case processing
      • 3.10.4.2 ADR Reporting
      • 3.10.4.3 Medical writing
      • 3.10.4.4 Drug safety management
  • 3.11 Technology Timeline Overview
    • 3.11.1 Changing Technology & Adoption
      • 3.11.1.1 Social Media
      • 3.11.1.2 Literature screening
      • 3.11.1.3 Automation and AI
      • 3.11.1.4 Big data analytics in PV

Chapter 4 COVID-19 Impact Analysis

  • 4.1 COVID-19 Outbreak
    • 4.1.1 U.K.: COVID-19 Disease Prevalence
  • 4.2 Current and Future Impact Analysis
  • 4.3 Recent Developments & Strategic Outcomes
    • 4.3.1 Regulatory requirements/changes due to Covid-19
    • 4.3.2 Strategies implemented by companies
      • 4.3.2.1 IQVIA
      • 4.3.2.2 PARAXEL International Corporation
      • 4.3.2.3 Bioclinica
      • 4.3.2.4 Pharmaceutical Product Development (PPD)
      • 4.3.2.5 IBM Corporation
      • 4.3.2.6 ICON, plc
      • 4.3.2.7 ArisGlobal

Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

  • 5.1 Service Provider Market Share Analysis, 2020 & 2028
  • 5.2 Service Provider Dashboard
    • 5.2.1 In-house
      • 5.2.1.1 In-house market estimates and forecasts, 2016 - 2028 (USD Million)
    • 5.2.2 Contract Outsourcing
      • 5.2.2.1 Contract outsourcing market estimates and forecasts, 2016 - 2028 (USD Million)

Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis

  • 6.1 Type Market Share Analysis, 2020 & 2028
  • 6.2 Type Dashboard
    • 6.2.1 Spontaneous Reporting
      • 6.2.1.1 Spontaneous Reporting market estimates and forecasts, 2016 - 2028 (USD Million)
    • 6.2.2 Intensified ADR Reporting
      • 6.2.2.1 Intensified ADR Reporting market estimates and forecasts, 2016 - 2028 (USD Million)
    • 6.2.3 Targeted Spontaneous Reporting
      • 6.2.3.1 Targeted spontaneous reporting market estimates and forecasts, 2016 - 2028 (USD Million)
    • 6.2.4 Cohort Event Monitoring (CEM)
      • 6.2.4.1 CEM market estimates and forecasts, 2016 - 2028 (USD Million)
    • 6.2.5 EHR Mining
      • 6.2.5.1 EHR Mining market estimates and forecasts, 2016 - 2028 (USD Million)

Chapter 7 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis

  • 7.1 Product Life Cycle Market Share Analysis, 2020 & 2028
  • 7.2 Product Dashboard
    • 7.2.1 Pre-clinical
      • 7.2.1.1 Pre-clinical market estimates and forecasts, 2016 - 2028 (USD Million)
    • 7.2.2 Phase I
      • 7.2.2.1 Phase I market estimates and forecasts, 2016 - 2028 (USD Million)
    • 7.2.3 Phase II
      • 7.2.3.1 Phase II market estimates and forecasts, 2016 - 2028 (USD Million)
    • 7.2.4 Phase III
      • 7.2.4.1 Phase III market estimates and forecasts, 2016 - 2028 (USD Million)
    • 7.2.5 Phase IV
      • 7.2.5.1 Phase IV market estimates and forecasts, 2016 - 2028 (USD Million)

Chapter 8 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

  • 8.1 Process Flow Market Share Analysis, 2020 & 2028
  • 8.2 Process Flow Dashboard
    • 8.2.1 Case data management
      • 8.2.1.1 Case data management market estimates and forecasts, 2016 - 2028 (USD Million)
      • 8.2.1.2 Case logging
      • 8.2.1.3 Case logging market estimates and forecasts, 2016 - 2028 (USD Million)
      • 8.2.1.4 Case data analysis
      • 8.2.1.5 Case data analysis market estimates and forecasts, 2016 - 2028 (USD Million)
      • 8.2.1.6 Medical reviewing and reporting
      • 8.2.1.7 Medical reviewing and reporting market estimates and forecasts, 2016 - 2028 (USD Million)
    • 8.2.2 Signal detection
      • 8.2.2.1 Signal detection market estimates and forecasts, 2016 - 2028 (USD Million)
      • 8.2.2.2 Adverse Event Logging
      • 8.2.2.3 Adverse Event Logging market estimates and forecasts, 2016 - 2028 (USD Million)
      • 8.2.2.4 Adverse Event Analysis
      • 8.2.2.5 Adverse Event Analysis market estimates and forecasts, 2016 - 2028 (USD Million)
      • 8.2.2.6 Adverse Event Review & Reporting
      • 8.2.2.7 Adverse Event Review & Reporting market estimates and forecasts, 2016 - 2028 (USD Million)
    • 8.2.3 Risk Management System
      • 8.2.3.1 Risk Management System market estimates and forecasts, 2016 - 2028 (USD Million)
      • 8.2.3.2 Risk Evaluation System
      • 8.2.3.3 Risk Evaluation System market estimates and forecasts, 2016 - 2028 (USD Million)
      • 8.2.3.4 Risk Mitigation System
      • 8.2.3.5 Risk Mitigation System market estimates and forecasts, 2016 - 2028 (USD Million)

Chapter 9 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

  • 9.1 Therapeutic Area Market Share Analysis, 2020 & 2028
  • 9.2 Therapeutic Area Dashboard
    • 9.2.1 Oncology
      • 9.2.1.1 Oncology market estimates and forecasts, 2016 - 2028 (USD Million)
    • 9.2.2 Neurology
      • 9.2.2.1 Neurology market estimates and forecasts, 2016 - 2028 (USD Million)
    • 9.2.3 Cardiology
      • 9.2.3.1 Cardiology market estimates and forecasts, 2016 - 2028 (USD Million)
    • 9.2.4 Respiratory systems
      • 9.2.4.1 Respiratory systems market estimates and forecasts, 2016 - 2028 (USD Million)
    • 9.2.5 Others
      • 9.2.5.1 Others market estimates and forecasts, 2016 - 2028 (USD Million)

Chapter 10 Pharmacovigilance Market: End-use Estimates & Trend Analysis

  • 10.1 End-use Market Share Analysis, 2020 & 2028
  • 10.2 End-use Dashboard
    • 10.2.1 Pharmaceuticals
      • 10.2.1.1 Pharmaceuticals market estimates and forecasts, 2016 - 2028 (USD Million)
    • 10.2.2 Biotechnology Companies
      • 10.2.2.1 Biotechnology companies market estimates and forecasts, 2016 - 2028 (USD Million)
    • 10.2.3 Medical Device Manufacturers
      • 10.2.3.1 Medical Device Manufacturers market estimates and forecasts, 2016 - 2028 (USD Million)
    • 10.2.4 Others
      • 10.2.4.1 Others market estimates and forecasts, 2016 - 2028 (USD Million)

Chapter 11 Competitive Outlook

  • 11.1 Market Participation Categorization
  • 11.2 Public Companies
    • 11.2.1 Company market position analysis
    • 11.2.2 Consolidation Trends
  • 11.3 Private Companies
    • 11.3.1 List of key emerging companies

Chapter 12 Company Profiles

  • 12.1 Accenture
    • 12.1.1 Company overview
    • 12.1.2 Service benchmarking
    • 12.1.3 Organization structure & Team Composition
      • 12.1.3.1 Team composition
    • 12.1.4 Financial performance
    • 12.1.5 R&D expenditure
    • 12.1.6 Strategic initiatives
    • 12.1.7 SWOT Analysis
  • 12.2 IQVIA
    • 12.2.1 Company overview
    • 12.2.2 Service benchmarking
    • 12.2.3 Organization structure & Team Composition
      • 12.2.3.1 Team composition
    • 12.2.4 Financial performance
    • 12.2.5 Strategic initiatives
    • 12.2.6 SWOT Analysis
  • 12.33 Cognizant
    • 12.3.1 Company overview
    • 12.3.2 Service benchmarking
    • 12.3.3 Organization structure & Team Composition
      • 12.3.3.1 Team composition
    • 12.3.4 Financial performance
    • 12.3.5 Strategic initiatives
    • 12.3.6 SWOT Analysis
  • 12.4 IBM Corporation
    • 12.4.1 Company overview
    • 12.4.2 Service benchmarking
    • 12.4.3 Organization structure & Team Composition
      • 12.4.3.1 Team composition
    • 12.4.4 Financial performance
    • 12.4.5 R&D expenditure
    • 12.4.6 Strategic initiatives
    • 12.4.7 SWOT Analysis
  • 12.5 ArisGlobal
    • 12.5.1 Company overview
    • 12.5.2 Service benchmarking
    • 12.5.3 Organization structure & Team Composition
      • 12.5.3.1 Team composition
    • 12.5.4 Financial performance
    • 12.5.5 Strategic initiatives
    • 12.5.6 SWOT Analysis
  • 12.6 ICON Plc.
    • 12.6.1 Company overview
    • 12.6.2 Service benchmarking
    • 12.6.3 Organization structure & Team Composition
      • 12.6.3.1 Team composition
    • 12.6.4 Financial performance
    • 12.6.5 Strategic initiatives
    • 12.6.6 SWOT Analysis
  • 12.7 Capgemini
    • 12.7.1 Company overview
    • 12.7.2 Service benchmarking
    • 12.7.3 Organization structure & Team Composition
      • 12.7.3.1 Team composition
    • 12.7.4 Financial performance
    • 12.7.5 Strategic initiatives
    • 12.7.6 SWOT Analysis
  • 12.8 TAKE Solutions
    • 12.8.1 Company overview
    • 12.8.2 Service benchmarking
    • 12.8.3 Organization structure & Team Composition
      • 12.8.3.1 Team composition
    • 12.8.4 Financial performance
    • 12.8.5 Strategic initiatives
    • 12.8.6 SWOT Analysis
  • 12.9 PAREXEL International Corporation
    • 12.9.1 Company overview
    • 12.9.2 Service benchmarking
    • 12.9.3 Organization structure & Team Composition
      • 12.9.3.1 Team composition
    • 12.9.4 Financial performance
    • 12.9.5 Strategic initiatives
    • 12.9.6 SWOT Analysis
  • 12.10 BioClinica, Inc.
    • 12.10.1 Company overview
    • 12.10.2 Service benchmarking
    • 12.10.3 Organization structure & Team Composition
      • 12.10.3.1 Team composition
    • 12.10.4 Financial performance
    • 12.10.5 Strategic initiatives
    • 12.10.6 SWOT Analysis

Chapter 13 Winning Strategies

  • 13.1 Key Winning/Scoring Criteria's
    • 13.1.1 By categories
      • 13.1.1.1 Pharmaceuticals
      • 13.1.1.2 Biotech companies
      • 13.1.1.3 Medical device companies
  • 13.2 Key Vendor Selection Factors
    • 13.2.1 By Category
    • 13.2.2 BY Company size
      • 13.2.2.1 KEY TAKEAWAYS
  • 13.3 Switching Cost Analysis
  • 13.4 Detailed List of Companies